Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt ...

Core Viewpoint - Eli Lilly has experienced a decline in share price since reaching a $1 trillion market valuation, with concerns about its valuation and potential competition in the weight management market [1] Group 1: Market Position and Competition - Eli Lilly maintains a strong lead in the anti-obesity market, with new product launches expected to solidify its position and expand its market reach [2] - The company is preparing to launch orforglipron, an oral GLP-1 candidate, which could attract new patients who prefer oral therapies over subcutaneous options [2] - Orforglipron has shown strong clinical trial performance, positioning it as a potential best-in-class medicine in diabetes and obesity treatment [3] Group 2: Product Pipeline and Revenue Sources - Eli Lilly is targeting patients with high body mass indexes with retatrutide, which has demonstrated a remarkable 28.7% mean weight loss in a phase 3 study [3][4] - The company has a diverse portfolio beyond weight management, including billion-dollar drugs like Verzenio, which generated $5.7 billion in sales last year, and Taltz, which grew sales by 9% to $3.6 billion [6][7] - Eli Lilly's aggressive expansion into various therapeutic areas, including pain management, oncology, and immunology, supports its revenue growth strategy [7] Group 3: Valuation and Growth Potential - Eli Lilly trades at a forward earnings multiple of 27x, significantly higher than the healthcare sector average of 17.1x, reflecting its faster revenue and earnings growth compared to peers [8] - The company's deep pipeline of candidates is expected to drive growth in the medium term, making the stock attractive despite its premium valuation [8]

Eli Lilly’s experimental drug retatrutide met trial endpoints, showing significant weight loss and blood sugar reductions. https://t.co/t4a97OCbBI ...

Core Insights - Eli Lilly is well-positioned to attract future investments in India due to its strong scientific base, academic resources, and skilled workforce [1][10] - The company emphasizes the importance of regulatory data protection and a streamlined regulatory review process to enhance India's competitiveness in attracting high-value research [2][11] - Lilly's performance has been robust, driven by innovative medicines addressing significant unmet medical needs, with a positive outlook for future growth [7][8] Regulatory Environment - Regulatory data protection is crucial for the pharmaceutical industry, allowing companies to recoup investments made in clinical efficacy and safety data [2][5] - The regulatory review process in India involves three steps and can take up to one and a half years, which could be improved for faster approvals [2][11] - Harmonization with international guidelines for clinical trials is necessary to strengthen India's scientific capabilities and enable earlier access to innovative therapies [2][11] Market Dynamics - The affordability of medicines in India reflects the country's GDP per capita, ensuring that prices are significantly lower than in markets like Germany or the U.S. [6][11] - The innovative pharmaceutical industry is essential for the existence of generics, highlighting the interdependence between innovative and generic drug markets [5][11] Product Pipeline - Eli Lilly is expanding its product pipeline with significant developments in areas such as type 2 diabetes, obesity, Alzheimer's disease, and oncology [7][9] - The company plans to launch Donanemab for Alzheimer's in India by 2026, subject to regulatory approvals, and has an oral GLP-1 under review outside India [9][11] - Retatrutide, a triple agonist, has shown promising results with over 28% weight loss in studies, indicating strong potential in the obesity treatment market [9][11]

Eli Lilly has a R&D presence in India. What is the scale of Lilly's financial commitment to India going forward?India is well positioned to attract future investments. You look at the science, look at academia, look at the workforce, the talent, you know, I think you are super well positioned. Can it be improved further? Yes.I think there are also some additional things that could make India even more attractive for future investments. We saw some positive signs now with the announcement to increase accredi ...

2026.03. 22 应基地。阿斯利康表示，两个基地的协同将进一步增强阿斯利康在新型药物及疗法领域的本地化生产 能力，并成为其持续扩展多元化全球供应网络中的关键支柱。 上周，礼来公司也宣布了一项未来十年在中国累计投资30亿美元的计划，此举将全面扩展该公司在 华供应链产能，打造口服固体制剂本土生产与供应体系，为未来推向市场的口服小分子GLP-1受体 激动剂的生产能力提前做好布局。 中国持续火爆的减重药需求也是跨国医疗公司争夺的下一个重要市场。3月21日，礼来中国发布的一 项超重与肥胖经济负担研究显示，我国因超重与肥胖症带来的年度经济负担已达1万亿元人民币。礼 来CEO戴文睿表示，提升有效治疗手段的可及性，加快完善肥胖症管理体系，有望从源头上减轻社 会面临的长期慢病管理压力。 本月，辉瑞从中国生物药企先为达授权而来的一款GLP-1受体激动剂埃诺格鲁肽注射液也在中国获 得国家药品监督管理局正式批准上市，此举意味着辉瑞将正式入局中国减重药市场。 另一方面，随着跨国制药公司的多个重磅药物近年来将陆续迎来专利到期，这些企业也希望通过收购 中国的创新药物来充实研发管线。"中国早期研发如今已具备全球竞争力。"瑞银医药分析师 ...

China’s Commerce Minister Wang Wentao said he hopes Eli Lilly will deepen its commitment in the country and seek greater growth, according to a statement posted on the ministry’s website https://t.co/v5pCdhOiSu ...

Core Insights - Eli Lilly (LLY) announced positive results from a late-stage study of its weight-loss drug retatrutide for adults with type II diabetes, achieving significant reductions in A1C and body weight [1][2][3] Group 1: Study Results - The TRANSCEND-T2D-1 study met its primary endpoint, showing A1C reductions of 1.7% to 2% for retatrutide compared to 0.8% for placebo under the efficacy estimand [2] - Patients taking retatrutide lost up to 16.8% of their body weight, while the placebo group lost 2.5% under the efficacy estimand [3] - The study evaluated three doses of retatrutide (4 mg, 9 mg, and 12 mg) over 40 weeks against a placebo [1] Group 2: Drug Mechanism and Competitors - Retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon, compared to Eli Lilly's Zepbound, which targets GLP-1 and GIP, and Novo Nordisk's Wegovy, which activates only GLP-1 [5] - The obesity market is competitive, with Eli Lilly and Novo Nordisk leading in injectable therapies, while both companies are also racing to introduce oral weight-loss pills [9][10] Group 3: Future Developments - Eli Lilly is conducting multiple late-stage studies for retatrutide across various cardiometabolic conditions, with results from additional studies expected later this year [4] - The FDA is currently reviewing Eli Lilly's obesity pill orforglipron, with a decision anticipated soon [10]

Eli Lilly and Company (NYSE:LLY) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the market. A caller asked if the stock is a buy, sell, or hold, and Cramer replied: Okay, everybody’s giving up on Lilly. My experience with Eli Lilly is there are bouts of giving up in this. That’s what I call it, giving up in this. We’re in a giving up in this moment for one of the greatest, if not the greatest, drug company in history. I think the pill is going to be gigantic. ...

大健康 | 2026 年 3 月 20 日 诺和诺德 | NVO US 静待价值重估 全球代谢龙头诺和诺德 (Novo Nordisk, NVO US) 的估值修复。公司正 处于一个独特的历史交汇点：股价在 2025 年经历回调，估值压缩，市场 忽视了公司在核心糖尿病领域的稳固份额及在全球肥胖市场的长期领先 统治力。短期催化剂有产能释放带来的业绩反弹，中期有 CagriSema 和口服新药的确证性数据，长期有 Amycretin 和新适应症拓展带来的第 二营收增长空间。这种由过渡期阵痛引发的抛售，与公司长期稳健的基 本面形成背离，创造具吸引力的入场点。 2026 年估值逻辑与股价回升。模型遵循管理层-5%至-13%的指引，假设 公司 2026 年调整后销售与营业利润将可能出现分别约 -6%及-9%的下 滑。而 13 倍的 2026 年预期市盈率 (P/E)反映了市场开始透过短期负增 长的迷雾，提前定价 2027 年的反弹。13 倍 P/E 对应的是公司作为 GLP- 1 龙头的溢价，以及对利空出尽的预期。一旦 340B 尘埃落定且重组完 成，优于-13%下限的表现可能成为惊喜。2025 年的回调主要受市场对产 ...